

- Teriflunomide is a once-daily, oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis (MS).
- All newborns from female teriflunomide patients and partners of male patients were healthy and did not have any structural or functional abnormalities at birth, indicating no teratogenic signal.
- These data are consistent with observations from a prospective study by the Organization of Teratology Information Specialists and the extensive postmarketing surveillance (2.46 million patient-years of exposure), which have not demonstrated any teratogenic effect of the parent compound, leflunomide.
- Teriflunomide is an effective therapeutic option for patients with MS, including women of childbearing potential using effective contraception.

This summary slide represents the opinions of the authors. Editorial support was provided by Scott Chambers, of Fishawack Communications Ltd, Abingdon, UK, and was funded by Genzyme. No other funding or sponsorship was received for this study or publication of this article. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).